Triad Isotopes

What Triad Isotopes does

Triad Isotopes, founded in 2006 and headquartered in Orlando, Florida, is a US-based for-profit company operating in the radiopharmaceutical and nuclear medicine sector. Per firmographic data, the company employs 501-1,000 professionals and serves radiopharmaceutical-based nuclear medicine across its facilities. The company was founded by Domenic Meffe (founder and CEO) and received early-stage capital from Parthenon Capital Partners in January 2007. Detailed product, network, and operational data supplied for the company is heavily aligned with a second-largest-in-US radiopharmacy operation comprising 42 SPECT pharmacies, 3 PET manufacturing facilities, 300+ in-house medical couriers, and an annual throughput exceeding 3 million doses to 1,800+ healthcare providers.

Triad Isotopes' core offering is the manufacture, distribution, and delivery of radiopharmaceuticals spanning PET, SPECT, therapeutic, and ancillary products to hospitals and diagnostic imaging centers. The technology stack centers on time-sensitive cold-chain logistics for short-half-life isotopes, supported by an online prescription ordering platform and a GeoTab real-time delivery tracking system that provides 15-minute delivery timeslots and Saturday delivery. Service differentiation emphasizes nationwide coverage, open-formulary product breadth, and precision delivery windows critical to nuclear medicine workflows.

The business model is a transaction-fee radiopharmaceutical distribution and dose-preparation service sold primarily to enterprise hospital customers. Go-to-market combines direct field sales with channel partnerships via Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs), enabling reach into large hospital networks. Revenue is generated per dose delivered, with $60 million committed to future network expansion. The company has indicated 30+ years of nuclear medicine experience and self-describes as one of the fastest-growing radiopharmacy networks in the United States. Data gaps: no first-party revenue, headcount, or ownership disclosure is available for Triad Isotopes specifically, and much of the operational detail in the source material pertains to the related Jubilant Radiopharmacies business.

Name

Triad Isotopes

Website

https://triadisotopes.com

Company type

Private

Founded year

2006

Headcount range

501–1,000 employees

Short description

Triad Isotopes, founded 2006 in Orlando, FL, is a US radiopharmaceutical company that manufactures and distributes PET, SPECT, therapeutic, and ancillary nuclear medicine products to hospitals and healthcare providers through a nationwide pharmacy and courier network.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Manufacturing & Distribution

NAICS

Chemical Manufacturing (325)

SIC

Chemicals & Allied Products (2800)

akta.pro primary industry

Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE)

akta.pro secondary industries

Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE), Radiopharmaceutical & Nuclear Medicine Distributors (HLAIAJAI)

Keywords

• Radiopharmaceutical manufacturing
• Nuclear medicine distribution
• PET imaging products
• SPECT imaging products
• Radiopharmacy services

Headquarters

HQ city

Orlando

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Radiopharmaceutical Products: Manufacturing and delivering radiopharmaceuticals (PET, SPECT, therapeutic products) to healthcare facilities. The company is described as serving 1,800+ healthcare providers and delivering 3 million+ doses annually.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Triad Isotopes specializes in radiopharmaceuticals and nuclear medicine, manufacturing and distributing PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) radiopharmaceuticals, therapeutic radiopharmaceuticals, and ancillary dose-preparation products. The company operates a radiopharmacy network serving hospitals and healthcare providers with time-sensitive radiopharmaceutical supply, precision delivery via in-house medical couriers, and an online prescription ordering platform.

Product overview

The company operates a radiopharmacy network offering PET and SPECT radiopharmaceuticals and end-to-end total nuclear medicine solutions. The product portfolio consists of four core product lines: SPECT Products (for standard nuclear medicine procedures), PET Products (supporting diagnostic and therapeutic needs with advances in theranostics), Therapeutic Products (advanced radiotherapeutics), and Ancillary Products (essential support items for dose preparation). Supporting services include an Online Prescription Ordering Platform for secure prescription transmission and GeoTab Delivery Tracker for real-time delivery updates. The company operates 42 SPECT pharmacies and 3 PET manufacturing facilities nationwide.

Differentiator

Problem solved

Functional benefit

Products and services

• PET Products

Quantifiable outcome

• 3 million+ doses delivered annually
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• Group Purchasing Organizations (GPOs)coreChannel Partner/ Reseller/ DistributorJubilant Radiopharmacies has expertise in supporting Group Purchasing Organizations (GPOs), indicating partnerships with GPO entities to serve member healthcare facilities.
• Integrated Delivery Networks (IDNs)coreChannel Partner/ Reseller/ DistributorJubilant Radiopharmacies supports Integrated Delivery Networks (IDNs), indicating partnerships to serve member hospitals and healthcare facilities within these networks.
• Jubilant Pharmova LimitedflagshipStrategic or Co-development PartnerJubilant Radiopharmacies is a division of Jubilant Draximage, Inc., which is A Jubilant Pharma Company. The parent company provides corporate infrastructure and brand credibility (Jubilant Pharmova Limited certification badge visible on website).

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• GE HealthCare: Major medical imaging OEM with adjacent nuclear medicine equipment, tracer partnerships, and distribution footprint. Overlaps with the subject in the broader nuclear medicine ecosystem.
• Bayer Radiology: Large diversified pharma with a radiology contrast and imaging portfolio including some nuclear medicine offerings. Competes in adjacent diagnostic imaging channels rather than pure radiopharmacy distribution.

Direct peers

• PETNET Solutions (Siemens Healthineers): Siemens-owned radiopharmacy network producing and distributing PET radiopharmaceuticals to hospitals across the U.S. Competes head-to-head in PET supply chain and shares the same hospital customer base.
• Cardinal Health Nuclear Pharmacy Services: Operates the largest U.S. radiopharmacy network delivering unit-dose radiopharmaceuticals (SPECT and PET) to hospitals and clinics. Direct competitor to Triad/Jubilant with similar compounding, distribution, and GPO contracting model.
• Lantheus Holdings: Specialty radiopharmaceutical company focused on diagnostic imaging agents (e.g., DEFINITY, Neurolite) and emerging therapeutic radiopharmaceuticals. Direct competitor in the SPECT/PET/theranostics product space.
• Curium Pharma: Global nuclear medicine company manufacturing SPECT, PET, and therapeutic radiopharmaceuticals. Competes in both diagnostic and emerging therapeutic (Lu-177) categories serving overlapping hospital customers.
• Bracco Diagnostics: Manufactures and distributes diagnostic imaging agents including nuclear medicine products. Operates in the same radiopharmaceutical supply chain serving hospitals and imaging centers.

Emerging players

• Telix Pharmaceuticals: Develops and commercializes therapeutic and diagnostic radiopharmaceuticals (e.g., Illuccix for PSMA PET). Competes in theranostics product category and uses similar radiopharmacy distribution channels.
• Radiomedix: Radiopharmaceutical manufacturer specializing in theranostics (e.g., AlphaMedix for neuroendocrine tumors) and contract manufacturing. Comparable in the therapeutic radiopharmaceutical product category.
• SOFIE Biosciences: Radiopharmacy and contract manufacturing network focused on theranostics and PET tracer supply for clinical and academic sites. Smaller but directly comparable radiopharmacy operating model.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/triadisotopes
• LinkedInlinkedin.com/company/triad-isotopes

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triad Isotopes